Lisa G. Horvath
A5084855225- Prostate Cancer Treatment and Research
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Epigenetics and DNA Methylation
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Prostate Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Immunotherapy and Immune Responses
- Metabolomics and Mass Spectrometry Studies
- Ferroptosis and cancer prognosis
- Cancer-related gene regulation
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Treatments and Mutations
- Advanced Proteomics Techniques and Applications
- Cancer-related molecular mechanisms research
- PARP inhibition in cancer therapy
- RNA modifications and cancer
- Cancer Cells and Metastasis
- Chemotherapy-related skin toxicity
- Medical Imaging Techniques and Applications
- Cell Adhesion Molecules Research
- MicroRNA in disease regulation
- Wnt/β-catenin signaling in development and cancer
Chris O’Brien Lifehouse
2016-2025
Royal Prince Alfred Hospital
2016-2025
The University of Sydney
2016-2025
Garvan Institute of Medical Research
2015-2024
St Vincent's Health
2022-2024
UNSW Sydney
2012-2024
St Vincent's Clinic
2010-2024
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
2024
The Kinghorn Cancer Centre
2013-2023
National Cancer Centre Japan
2002-2023
Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, or without early docetaxel, will improve metastatic, hormone-sensitive cancer.In this open-label, randomized, phase 3 trial, we assigned patients receive suppression plus either open-label a standard nonsteroidal antiandrogen therapy (standard-care group). The primary end point...
Purpose Biliary cancers overexpress epidermal growth factor receptor (EGFR), and angiogenesis has been correlated with poor outcome. Erlotinib, an EGFR tyrosine kinase inhibitor, bevacizumab, a vascular endothelial (VEGF) inhibitor have each shown to activity in biliary cancer. The primary objective of this study was evaluate the response rate by Response Evaluation Criteria Solid Tumors (RECIST). Secondary end points included overall survival (OS), time progression (TTP), VEGF levels,...
Prostate-specific membrane antigen (PSMA) may be targeted for both diagnostic and therapeutic purposes in the management of prostate cancer (PCa). In preclinical models, androgen blockade (AB) increases expression PSMA hormone-sensitive castrate-resistant xenotypes. The aim this study was to evaluate effect AB treatment on <sup>68</sup>Ga-PSMA-11 PET imaging hormone-naive (luteinizing hormone-releasing hormone [LHRH] ± bicalutamide) men (enzalutamide or abiraterone) with metastatic PCa....
Fatty acid β-oxidation (FAO) is the main bioenergetic pathway in human prostate cancer (PCa) and a promising novel therapeutic vulnerability. Here we demonstrate efficacy of targeting FAO clinical tumors cultured ex vivo, identify DECR1, encoding rate-limiting enzyme for oxidation polyunsaturated fatty acids (PUFAs), as robustly overexpressed PCa tissues associated with shorter relapse-free survival. DECR1 negatively-regulated androgen receptor (AR) target gene and, therefore, may promote...
Innovations in imaging and molecular characterisation the evolution of new therapies have improved outcomes advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas management.To present consensus voting results for select questions from APCCC 2022.Before conference,...
Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts key questions clinical management order supplement evidence-based guidelines. Here present voting results for from APCCC 2024.
Abstract Background: Epigenetic alterations are common in prostate cancer, yet how these modifications contribute to carcinogenesis is poorly understood. We investigated whether specific histone prognostic for cancer relapse, and the expression of epigenetic genes altered tumorigenesis. Methods: Global levels H3 lysine-18 acetylation (H3K18Ac) lysine-4 dimethylation (H3K4diMe) were assessed immunohistochemically a cohort 279 cases. gene was silico by analysis microarray data from 23 primary...
Docetaxel is the first-line chemotherapy for castration-resistant prostate cancer (CRPC). However, response rates are ∼50% and determined quite late in treatment schedule, thus non-responders subjected to unnecessary toxicity. The potential of circulating microRNAs as early biomarkers docetaxel CRPC patients was investigated this study. Global microRNA profiling performed on docetaxel-resistant sensitive cell lines identify candidate biomarkers. Custom Taqman Array MicroRNA cards were used...
Circulating microRNAs (miRNAs) are emerging as promising biomarkers for prostate cancer. Here, we investigated the potential of these molecules to assist in prognosis and treatment decision-making.MicroRNAs serum patients who had experienced rapid biochemical recurrence (BCR) (n=8) or no following radical prostatectomy (RP) were profiled using high-throughput qRT-PCR. Recurrence-associated miRNAs subsequently quantitated by qRT-PCR a validation cohort comprised 70 with Gleason 7 cancers...
Taxanes are the only chemotherapies used to treat patients with metastatic castration-resistant prostate cancer (CRPC). Despite initial efficacy of taxanes in treating CRPC, all ultimately fail due development drug resistance. In this study, we show that ERG overexpression vitro and vivo models CRPC is associated decreased sensitivity taxanes. affects several parameters microtubule dynamics inhibits effective drug-target engagement docetaxel or cabazitaxel tubulin. Finally, analysis a cohort...